// App-Quantinova.ai

3218 : Disruption of the CD39 immune checkpoint pathway increases the efficacy of various anticancer therapies in syngeneic mouse models

Researchers

Presenter

  • Marion Lapierre

Principal Investigators

  • Cecile Dejou

  • Carine Paturel

  • Henri-Alexandre Michaud

  • Laurent Gros

  • Armand Bensussan

  • Jean-Francois Eliaou

  • Jeremy Bastid

  • Nathalie Bonnefoy

Medical Centers

  • OREGA Biotech, Ecully, France

  • Innate Pharma, Marseille, France

  • IRCM, Montpellier, France

  • INSERM, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Fibroblastic sarcoma

  • Melanoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Adenosine

  • Adenosine Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved